Amgen (AMGN) Price & Analysis

Compare

6,477 Followers

AMGN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$253.30 - $346.85

Previous CloseN/A

Volume614.18K

Average Volume (3M)2.71M

Market Cap

$146.07B

Enterprise Value$191.48B

Total Cash (Recent Filing)$8.81B

Total Debt (Recent Filing)$57.38B

Price to Earnings (P/E)24.8

Beta0.36

Next Earnings

Aug 05, 2025

EPS Estimate

5.23

Last Dividend Ex-Date

May 16, 2025

Dividend Yield3.36%

Share Statistics

EPS (TTM)4.90

Shares Outstanding537,706,100

10 Day Avg. Volume2,878,492

30 Day Avg. Volume2,713,014

Financial Highlights & Ratios

PEG Ratio0.53

Price to Book (P/B)23.04

Price to Sales (P/S)0.00

P/FCF Ratio13.09

Enterprise Value/Market Cap1.31

Enterprise Value/Revenue1.46

Enterprise Value/Gross Profit8.91

Enterprise Value/Ebitda3.91

Forecast

1Y Price Target

$325.00

Price Target Upside16.30% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering21

Amgen News

See All News >

Bulls Say, Bears Say

Bulls Say

Financial PerformanceAmgen's Q1 results beat consensus on both total revenue and EPS.

Pipeline DevelopmentAmgen's key pipeline asset, MariTide, offers the potential of less frequent dosing compared to currently marketed weekly injectable GLP-1 medications.

Product DiversificationSales of biosimilars like Wezlana and Pavblu were strong, indicating successful diversification of product offerings.

Bears Say

Competition ImpactAMGN anticipates sales erosion from biosimilar competition in the second half of the year.

Market CompetitionThe analyst reiterates an underperform rating with a price objective of $252, which is below the current trading price of $283.78.

R&D SpendingRevenue and EPS forecasts for 2026 and beyond are expected to be moderately lower due to increased R&D spending and potential generic erosion.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.19% Insiders

23.54% Mutual Funds

20.51% Other Institutional Investors

28.07% Public Companies and Individual Investors

Detailed Ownership Overview >

AMGN FAQ

What was Amgen’s price range in the past 12 months?

Amgen lowest stock price was $253.30 and its highest was $346.85 in the past 12 months.

What is Amgen’s market cap?

Amgen’s market cap is $146.07B.

When is Amgen’s upcoming earnings report date?

Amgen’s upcoming earnings report date is Aug 05, 2025 which is in 69 days.

How were Amgen’s earnings last quarter?

Amgen released its earnings results on May 01, 2025. The company reported $4.9 earnings per share for the quarter, beating the consensus estimate of $4.27 by $0.63.

Is Amgen overvalued?

According to Wall Street analysts Amgen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Amgen pay dividends?

Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3.36%. See more information on Amgen dividends here

What is Amgen’s EPS estimate?

Amgen’s EPS estimate is 5.23.

How many shares outstanding does Amgen have?

Amgen has 537,706,100 shares outstanding.

What happened to Amgen’s price movement after its last earnings report?

Amgen reported an EPS of $4.9 in its last earnings report, beating expectations of $4.27. Following the earnings report the stock price went down -0.899%.

Which hedge fund is a major shareholder of Amgen?

Currently, no hedge funds are holding shares in AMGN

Amgen Stock Smart Score

Neutral

Fundamentals

Return on Equity

105.67%

Trailing 12-Months

Asset Growth

-3.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Amgen

Amgen Inc. (AMGN) is a leading biotechnology company headquartered in Thousand Oaks, California. The company is dedicated to advancing healthcare by discovering, developing, manufacturing, and delivering innovative human therapeutics. Its core products are primarily in the areas of oncology, nephrology, cardiovascular disease, inflammation, and bone health. Amgen's product portfolio includes well-known drugs such as Enbrel, Neulasta, Prolia, and Xgeva, which are used to treat serious illnesses and improve the quality of life for millions of patients globally.

AMGN Company Deck

AMGN Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong performance with notable revenue and volume growth, successful biosimilar launches, and strategic expansions. However, there are concerns regarding potential impacts from tariffs and tax uncertainties, as well as challenges in maintaining inventory levels in the rare disease segment.Read More>

AMGN Revenue Breakdown

13.09% Prolia

9.92% Enbrel

6.66% XGEVA

6.65% Repatha

63.69% Other

AMGN Stock 12 Month Forecast

Average Price Target

$325.00

▲(16.30%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"251":"$251","326":"$326","401":"$401","288.5":"$288.5","363.5":"$363.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$400.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$325.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":252,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$252.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[251,288.5,326,363.5,401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,281.29,290.4215384615385,299.55307692307696,308.6846153846154,317.81615384615384,326.9476923076923,336.0792307692308,345.21076923076924,354.3423076923077,363.4738461538461,372.60538461538465,381.73692307692306,390.86846153846153,{"y":400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,281.29,284.6523076923077,288.0146153846154,291.3769230769231,294.7392307692308,298.1015384615385,301.46384615384613,304.82615384615383,308.1884615384615,311.5507692307692,314.9130769230769,318.2753846153846,321.6376923076923,{"y":325,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,281.29,279.0369230769231,276.7838461538462,274.53076923076924,272.27769230769235,270.0246153846154,267.77153846153846,265.51846153846157,263.2653846153846,261.0123076923077,258.7592307692308,256.50615384615384,254.25307692307692,{"y":252,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":266.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":296.29,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":301.29,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.65,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":312.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":311.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":280.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":281.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >